Physician profile
Melissa Moore
NPI 1962865410
$25,627.73
in general payments reported to CMS, 2019-2025
17 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $218 · 2023: $905 · 2024: $5,838 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,675 · Food and Beverage: $3,504 · Travel and Lodging: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $16,101.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,675.00 |
| Food and Beverage | $3,503.92 |
| Travel and Lodging | $1,003.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17,384.37 | 2025 | Symbravo |
| Pfizer INC. | $5,271.23 | 2023-2025 | |
| Abbvie INC. | $1,649.45 | 2021-2025 | |
| Ipsen Innovation | $515.00 | 2023 | Dysport |
| Amgen INC. | $166.57 | 2021-2022 | |
| Lundbeck LLC | $143.30 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $141.76 | 2024-2025 | Ajovy |
| Lilly USA, LLC | $118.26 | 2023-2025 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $65.11 | 2021 | |
| Tonix Medicines, INC. | $57.50 | 2024-2025 | Zembrace Symtouch |
| Impel Pharmaceuticals LLC | $52.87 | 2025 | Trudhesa |
| Allergan, INC. | $16.81 | 2021 | |
| Ucb, INC. | $15.50 | 2025 | Nayzilam |
| Scilex Pharmaceuticals INC. | $15.44 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.56 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.